Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25904264 | 0.85 | AOC3 (0.57) | AOC3KMT2AMAPTHRH3MEN1 | |
| SCHEMBL25317219 | 0.83 | AOC3 (0.60) | AOC3HRH3 | |
| SCHEMBL25315042 | 0.81 | AOC3 (0.53) | AOC3HRH3 | |
| SCHEMBL25903923 | 0.80 | GPR119 (0.49) | KMT2ATDP1MAPTMAPK1EPHX2 | |
| SCHEMBL26030108 | 0.79 | AOC3 (0.35) | AOC3KMT2ATDP1MAPTMAPK1 | |
| SCHEMBL26022348 | 0.78 | GPR119 (0.43) | KMT2ATDP1MAPTMAPK1EPHX2 | |
| SCHEMBL22713834 | 0.78 | AOC3 (0.53) | AOC3HTR2B | |
| SCHEMBL29798486 | 0.78 | AOC3 (0.53) | AOC3HTR2B | |
| SCHEMBL26022350 | 0.76 | HRH3 (0.40) | KMT2ATDP1MAPTMAPK1HRH3 | |
| SCHEMBL24481560 | 0.73 | AOC3 (0.42) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | AOC3 152/4885KMT2A 4715/4885TDP1 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.